← Back to Search

Anticoagulant

Ticagrelor first for Heart Attack (DEFINE CCS Trial)

Phase 4
Recruiting
Research Sponsored by Nova Scotia Health Authority
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights

DEFINE CCS Trial Summary

This trial will compare two drug treatments in heart attack survivors to see which one has fewer risks of bleeding/clotting. Both treatments are already approved for heart attack patients.

Eligible Conditions
  • Heart Attack
  • Blood Clot

DEFINE CCS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Bleeding time
Secondary outcome measures
Differential effects on fibrin clot lysis time
Differential effects on inflammatory markers (white cell count and CRP)

DEFINE CCS Trial Design

2Treatment groups
Active Control
Group I: Ticagrelor firstActive Control2 Interventions
Patients will be treated with ticagrelor 60 mg twice a day for one week then on Day 21, will be treated with rivaroxaban 2.5 mg twice a day for one week.
Group II: Rivaroxaban firstActive Control2 Interventions
Patients will be treated with rivaroxaban 2.5 mg twice a day for one week then on Day 21, will be treated with ticagrelor 60 mg twice a day for one week.

Find a Location

Who is running the clinical trial?

Nova Scotia Health AuthorityLead Sponsor
258 Previous Clinical Trials
83,824 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Was Ticagrelor the inaugural medication given FDA approval?

"Our assessment of Ticagrelor's safety is rated a 3. This result comes from the fact that it has cleared Phase 4 clinical trials, and thus been approved by regulatory bodies."

Answered by AI

What is the traditional application of Ticagrelor?

"Ticagrelor is commonly used to alleviate the symptoms of acute chest syndrome but can also be prescribed as a preventative measure against thrombosis, systemic embolism and cardiovascular mortality."

Answered by AI

Are there still opportunities for participants to join this experiment?

"Yes, according to clinicaltrials.gov the trial is currently recruiting participants. First posted on November 1st 2021 and last updated on September 21st 2023, this study requires 30 patients at a single location."

Answered by AI

How many participants are presently engaged in this research?

"Affirmative. The information on clinicaltrials.gov demonstrates that this research is actively recruiting volunteers, which commenced recruitment with a posting date of 11/1/2021 and was most recently updated on 9/21/2023. 30 participants need to be recruited from just one site for the study to proceed."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
Wael Sumaya 2021. "Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05116995.
All > Xarelto > Brilinta
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top